ABSTRACT: New treatment options are urgently required in the field of chondrosarcoma, particularly of chondrosarcomas with a welldifferentiated hyaline cartilage-like extracellular matrix (e.g., collagen II and proteoglycan-rich) phenotype, notoriously resistant to drug penetration, and having potential of progression towards higher grade. We investigated the feasibility of using 5 0 -methylschweinfurthin G (MeSG) as a tumor suppressor agent in the Swarm rat chondrosarcoma, an intermediate-to high-grade chondrosarcoma model, having a hyaline cartilage-like phenotype. Tumor cell culture studies were performed to identify their proliferative and cytotoxicity sensitivity to MeSG. Tumor burden mice were treated with MeSG and analyzed for tumor growth, morphology and regression. The chondrosarcoma tumor cells had a half maximum cytotoxicity concentration (IC 50 ) of 35 nM MeSG; approximately 300-fold less than freshly isolated rat chondrocytes (IC 50 of 11 mM). Multiple injections of MeSG (20 mg/kg, body weight) resulted in reduced/eliminated tumor growth over a 17-day period in mice, and an 83% reduction (p ¼ 0.023) in tumor mass. Three out of ten MeSG treated mice had complete elimination of tumor. Tumors of treated mice had a decrease in chondrosarcoma cell proliferation (p ¼ 0.012) and an increase in cell death (p ¼ 0.030) compared with tumors of control mice. These findings in an animal model demonstrate the effectiveness of MeSG for treatment of rat chondrosarcomas, and may have the potential use as a therapeutic option for the difficult-to-treat intermediate-to high-grade hyaline cartilage-like chondrosarcoma. ß
Chondrosarcoma represents the second most common primary tumor of the bone, 1 comprising 25% of all bone tumors. 2 These tumors are essentially resistant to currently available chemotherapy and radiation treatment regimens. [3] [4] [5] Surgical intervention with resection of tumor with wide surgical margins [6] [7] [8] is the treatment of choice for chondrosarcoma, however even with wide margins there is a high-risk of local recurrence with high-grade as well as low-grade tumors. 7 At times, due to locations (e.g., pelvis) adequate tumor-free margins are difficult to obtain, dramatically reducing the cure rate of the disease. [6] [7] [8] [9] Recurrence of chondrosarcoma has the potential of progression toward a higher-grade of malignancy, [10] [11] [12] further emphasizing the complexity of treating chondrosarcoma.
New treatment options to improve patient outcomes and decrease mortality are urgently required in this field. 13 Under initiative of the National Cancer Institute (NCI) Developmental Therapeutics Program in search of anti-cancer agents from natural products a family of compounds, schweinfurthins, were isolated from the plant Marcaranga species 14, 15 from which a series of synthetic natural products and analogs of the schweinfurthins have been developed, with high potency in cancer cell growth inhibition and lethality. 14 Utilizing the NCI-60 human tumor cell-line panel, schweinfurthins showed selectivity in cancer cell line growth inhibition, for example, glioblastoma multiforme-derived SF-295 line, showed a low nanomolar inhibition of growth and a 1,000-fold selectivity compared to resistant cell-lines such as the non-small cell lung cancer-derived A549. 16 Limited information is available on the mechanism by which schweinfurthins, prenylated stilbenes, inhibit select cancer cell growth and lethality. Studies with the SF-295 cell line identified schweinfurthin's ability to disrupt cholesterol homeostasis, and proposed subsequent inhibition of cell growth. 17 A recent study, not available on the onset of our study, suggested potent antiproliferative activity in select cancers (glioblastoma multiformederived SF-539 and B-lymphoma, WSU-DLCL2) was associated with schweinfurthin A disruption of intracellular trans-Golgi network trafficking that leads to endoplasmic reticular stress, and dysregulation of cell proliferation via the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapmaycin-C1 (mTORC1) signaling pathway. 18 We chose to examine the efficacy of the synthetic analog, 5 0 -methylschweinfurthin G (MeSG) as a new treatment option for chondrosarcomas with welldifferentiated hyaline cartilage-like extracellular matrix (e.g., collagen II and proteoglycan-rich) phenotype, notoriously resistant to drug penetration and having potential Conflicts of interest: The complete disclosures of potential conflicts of interest submitted by authors are always provided with the online version of the article. Ã Dedicated to Margaret and Richard Ling and family for the loss of their son Ben to chondrosarcoma and for their continued dedication in support to sarcoma research and sarcoma patient family members. 20, 21 Intramedullary transplantation of SRC shows radiographic change, 19, 22 destruction of bone cortex 19, 22 histological grade II and foci of grade III. Intraosseous, while not subcutaneous, transplantation of SRC is shown capable of colonizing to the lung. 19, 20, 23 We chose to use the SRC cell line, LM1, with the ability to utilize the engineered expression of luciferase 20 in ex vivo monitoring of tumor growth and tumor burden in mice.
METHODS

Cultured Cells
LM1 is a clonal cell line, originating from a SRC tumor that colonized to the lung following subcutaneous propagation of the rat SRC LTC cell line 24, 25 20 LM1 and isolated chondrocyte cells were plated in complete growth media consisting of DMEM (Dulbecco's minimal essential medium, high glucose, 4.5 gm/l, Gibco), 12% fetal bovine serum (FBS, Gibco), 25 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), and gentamycin at 50 mg/ml. Mono-disperse LM1 cells were cultured in alginate beads (1.2 Â 10 4 cells/bead, 15 ml/bead) following a procedure previously described 26 and maintained in complete growth medium. SF295 (human glioblastoma) cells were cultured in RPMI1640 media and A549 (human non-small cell lung cancer) cells were cultured in F12 media, and both cell lines were supplemented with FBS (10%), L-glutamine (2 nM), penicillin/streptomycin (1000 Units/ml, 100 mg/ml, respectively), and amphotericin B (2.5 mg/ml).
17
MTT Cell Metabolic Activity Assessment
As a colorimetric assay for measuring cellular metabolic activity via NAD(P)H-dependent cellular oxidoreductase enzymes the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (EMD Millipore, Darmstadt, Germany) assay of plated cells in culture was previously described. 17 
Animals
All animal experimentation was performed in accordance with the Guide for the Care and Use of Laboratory Animals, National Institutes of Health, and was approved by the University of Iowa Institutional Animal Care and Use Committee (Animal Protocol number 1308158). Mice were maintained in the University of Iowa barrier rodent facility, which is an AAALAC approved, virus-and pathogen-free (condition using SPF-BF barriers) facility, rooms maintained with a light/dark cycle À6:00 am À6:00 pm and a temperature of 21˚C. Mice (up to four companions per cage) were housed in suspension plastic polycarbonate cages 11 Â 7 Â 6 inches supplied with Softzorb bedding (NEPCO, Warrensburg, NY). Mice received 7,913 irradiated mouse/rat chow from Envigo (Madison, WI) and filtered water without restriction. This facility provides limited entry to trained personnel. Facilities for manipulation, dissection and disposal of animals are contained within this unit, and two full time veterinarians provide staffing. Mice were maintained in facilities covered under NIH assurance A3021-01 and are certified by the state of Iowa for use of living animals. The University of Iowa Animal Care Unit observes animals daily. The facility maintains a vigorous sentinel program for the detection of infections in each room of the housed mice. Sentinel mice are examined by serology testing for the presence of standard murine pathogens.
Athymic mice (Athymic Nude-Foxn1 nu ) were purchased from Harlan Sprague Laboratories (Indianapolis, IN). Nu/Nu strain consists of a mutation of the FOXN1 gene causing a deterioration or absence of the thymus, resulting in an inhibition of the immune system due to a greatly reduced number of T cells. This mouse was valuable to this study for its ability to receive Swarm rat chondrosarcoma grafts, as it mounts no rejection responds. 20 Animal sample size per group within each experiment was base on previous data identifying the number of LM1 chondrosarcoma cells for injection of athymic mice in order to produce sufficient reproducible tumors of similar size for study. 20 Mice were allocated to experimental groups using a randomization approach minimizing/eliminating any potential source of bias between control and treated groups, between mice, mice between cages, and within procedures performed (mouse weighing, dosing, and tumor measuring).
Xenografts
In the first xenograft experiment (Experiment (1), athymic mice, females 10 weeks of age, were subcutaneously injected with 0.5 Â 10 6 LM1 cells in 100 ml of a saline solution in the lower lumber region of the mouse. Following palatable appearance (9 days) of tumor, mice were divided into two groups: Group 1 (N ¼ 10, 22.77 AE 2.03 mg) control, subcutaneously injected with vehicle and Group 2 (N ¼ 11, 21.16 AE 1.17 mg) injected with MeSG at 20 mg/kg, body weight. Mice were injected for five consecutive days, and following an additional 3 days mice were euthanized and tumors harvested. In the second xenograft experiment (Experiment (2), athymic mice were injected with 0.5 Â 10 6 LM1 cells and following 5 days post-cell injections, mice were divided into two groups and subcutaneously injected with either vehicle alone (Group 1, N ¼ 8, 24.04 AE 1.41 mg, control) or MeSG at 50 mg/kg, body weight (Group 2, N ¼ 8, 22.25 AE 2.21 mg, MeSG). Vehicle consisted of a ternary mixture of American Food and Drug Administration (FDA) generally regarded as safe (GRAS) excipients. In this second experiment, tumors were harvested from euthanized mice following 7 days post-treatment. Throughout both experiments body weight, caliper measurements and bioluminescence imaging of the tumor was performed at 6:30-8:30 am throughout studies, until euthanasia (inhalation of carbon monoxide, 100% followed by thoracotomy) the tumors were harvested, weighed, and processed for histology. Caliber measurements were taken by measuring length (L) and width (W) in millimeters and the greatest and least distance, respectively, and volume (mm ). At termination of study excised tumors were processed for safranin-O/fast green staining (negatively-charge hyaline cartilage-like extracellular matrix) and Ki67 (cell proliferation) and caspase-3 (cell apoptosis) immunohistochemistry; performed by the Comparative Pathology Laboratory Core (University of Iowa). Sections were immunohistochemially stained for Ki67 27 and activated caspase-3 28 and evaluated using morphometric approaches with the pathologist blinded to groups using postexamination masking. 29 High-resolution digital images were collected (BX51 microscope, DP73 camera and CellSens software, Olympus, Center Valley, PA) and, if present, areas of overt necrosis were excluded from assessment. Percentage estimate of intact cells and vascular proliferation (extent of small capillaries immediately adjacent to the tumor borders) along the boarders of the tumors were determined from safranin-O/fast green stained sections. For the Ki67, cell nuclei were counted and labeled as positive or negative, and in a typical field produced a total count of 200-400þ nuclei. The "Ki67 index" was calculated as the percent of positive nuclei of this total. For the activated-caspase-3 sections, 4Â objective fields were digitized and to total number of immune-stained cells were enumerated and the data presented as the number of positive cells normalized to mm 2 of tumor tissue. (Fig. 1a) . Cells treated with 10 and 50 nM MeSG, at 48 h compared to time zero had a p ¼ 0.031 and p ¼ 0.37, respectively. MeSG treated cells rarely had two or three cells colonies. Trypan blue dye exclusion, at 48 h showed a statistically significant (p < 0.05) reduction in cell viability of 24.4% and 39.5% with 10 and 50 nM MeSG, respectively when compared to control cells (Fig. 1b) .
Statistical Analyses
MeSG Treatment of Tumor Burden Mice Reduces/Eliminates Chondrosarcomas
MeSG treatment (in comparison with vehicle treatment) of mice with a chondrosarcoma tumor showed no significant weight change (21.31 AE 1.36, treated vs. 24.14 AE 2.30, control); had less tumor growth (e.g., cell proliferation) and reduced net tumor weight at harvest and increased in cellular apoptosis. In Experiment 1, mice treated with MeSG, 20 mg/kg, body weight; daily for 5 days, 9 days post inoculation of tumor cells exhibited both a decrease in tumor volume (Fig. 2a) , and bioluminescence (Fig. 2b) from day 11 through, to (Fig. 2c and Table 2 ). The examination of groups of Experiment 1 showed a distinct effect of MeSG treatment on the morphologic appearance (intact vs. degenerate or necrotic cells), cellular biologics, and vascularity along the borders of the tumor (Fig. 4) Figure 6c . MeSG treatment also showed reduced vascularity around edges of tumor (20 AE 8% for MeSG versus 33 AE 17% for vehicle alone, p ¼ 0.03) ( Table 2) .
A single injection of MeSG (50 mg/kg, body weight) in Experiment 2, similarly reduced tumor growth and significantly affected the histological appearance of the tumor, and with no significant weight change (21.36 AE 2.24, treated versus 22.38 AE 1.43, control). Mice treated with a single injection of MeSG had both a statistically significant (p < 0.05) decrease in tumor volume (Fig. 2d) and bioluminescence (Fig. 2e) (Fig. 2f and Table 2 ). Histology, of MeSG treated mice showed a significant reduction (relative to vehicle, p < 0.05) in tumor cell proliferation (anti-Ki67 positive) and reduction in the number of intact cells and an increase in apoptosis (activated caspase-3) (Figs. 5b, and 6b, respectively, and Table 2 ). In contrast to mice receiving multiple injections of MeSG, mice receiving only a single injection of MeSG showed no difference in safranin-O staining and only a trend (p ¼ 0.18) in a decrease in neovascularization surrounding the tumor (Table 2) .
DISCUSSION
Chondrosarcoma represents the second most common malignant primary bone tumor, and is predominantly found in adults (mostly patients between 50 and 70 years old) with an annual incidence of one in 200,000. 30 Chondrosarcoma are notoriously resistant to common treatment methods. No significant improvement has occurred in the overall survival of patients with chondrosarcoma over the past few decades. Chemotherapy and radiotherapy have proven ineffective in management of chondrosarcoma. 7 Chemotherapeutic drugs resistance of chondrosarcoma is attributed in part to (i) poor vascularization and an often extensive extracellular matrix surrounding the cells, blocking accessibility of compounds to the neoplastic cells; (ii) high expression of multidrug resistance-associated protein P-glycoprotein 31 ; and (iii) relatively slow cell growth, reducing the efficacy of chemotherapeutic drugs that act on rapidly proliferating cells. 5, 32 Ineffectiveness of radiotherapy has been suggested related to the neoplasm's tissue hypoxia, as described in other tumors (e.g., head and neck cancers), preventing generation of radiation induced reactive oxygen species that cause DNA damage. 33 With ineffectiveness of radiotherapy and chemotherapy for treatment of chondrosarcoma surgical resection remains the treatment of choice for chondrosarcomas. A wide surgical margin of the cancer is essential for treatment efficacy, however this is not always obtainable, particularly in the spine and pelvis. 34, 35 This difficulty in obtaining wide surgical margins, inevitably leads to local recurrence, making clinical management of the cancer challenging.
Chondrosarcomas consist of a heterogeneous group of tumors possessing a hyaline cartilage-like phenotype. 30 Conventional chondrosarcoma, $85% of all chondrosarcomas, arise either centrally (in the medulla) or peripherally (at the surface) of bone, with a majority of primary tumors originating centrally. Histologically $90% of conventional chondrosarcoma are of a low-to intermediate-grade (grades I and II). Grades I and II is locally aggressiveness, low in metastatic potential, 36 and consists of an extensive hyaline cartilaginous extracellular matrix, sparse cellularity, and lack of cellular mitosis. The remaining ($10%) of conventional chondrosarcomas is of highgrade (grade III), showing an increased cellularity, mitotic activity, cellular pleomorphism, and commonly metastasize. The 10-year survival of grades I, II, and III conventional chondrosarcomas is 89-95, 58-86, and 0-55%, respectively, 10,37 while for unresectable tumors (e.g., of the pelvis) outcome is 48% at 1 year and 2% at 5 years. 38 Recurrence of conventional chondrosarcoma has the potential of progression towards a highergrade. 10, 11, 12 In a study of 36 patients, of conventional chondrosarcoma, who had undergone more than one Utilizing the rat chondrosarcoma model, having a conventional chondrosarcoma phenotype with a histological grade II/III 19, 20, 39 we show that the LM1 chondrosarcoma cells are extremely sensitive to MeSG (IC 50 of 35 nM, 48 h of treatment). This level of cytotoxic sensitivity is similar to human glioblastoma (IC 50 of 34 nM, 48 h of treatment), shown to be the most sensitive tumor line to schweinfurthins. 17 The cartilage-like extracellular matrix of welldifferentiated human chondrosarcoma cells has been shown to increase resistance to cytotoxicity of chemotherapeutic agents (e.g., mafosfamide, doxorubicin). 40 The cartilage-like well-differentiated LM1 cells cultured in alginate, a system that promoted the extensive accumulation of extracellular matrix, resulted in only a minor increase in resistance to MeSG treatment. LM1 cells suspended in alginate had a level of sensitivity in the low nanomolar values range (IC 50 ¼ 62 nM) similar to that of cells lacking their hyaline cartilage-like extracellular matrix. The extracellular matrix does not appear to obstruct accessibility of MeSG to the neoplastic cells, suggesting cells within well-differentiated cartilage-like tumors may be readily accessible to treatment with this agent. Interestingly, the high cytotoxicity sensitivity to MeSG is selective for the chondrosarcoma cells, as freshly isolated rat chondrocytes, were $300-fold less sensitive to MeSG treatment (IC 50 of 11 mM). Cytogenetics has revealed chromosomal abnormalities of the rat chondrosarcoma cells. 41 These chromosomal anomalies (and/or epigenetic dysregulation) we propose can potentially lead to the heighten cytotoxicity sensitivity of the neoplastic cells to MeSG, explaining the vulnerability of the well-differentiated cartilage-like chondrosarcoma specific to schweinfurthin. MeSG was extremely effective in reducing both cellular proliferation and apoptosis of the neoplasm generated in mice. Subcutaneous tumor encroachment (tumor mass) was reduces by 83% with multiple injections of MeSG (20 mg/kg, body weight). Three out of the 11 treated mice showed complete elimination of tumor. Extreme potency of MeSG was further shown in a separate experiment following a single dose of 50 mg/kg, body weight whereby a 63% reduction of tumor mass was obtained. Analysis of excised tumors showed reduced tumor cell proliferation, increased cellular apoptosis, reduced peripheral tumor vascularization, and increased necrotic sites within the tumors. All histological telltale signs that tumors of the MeSG treated mice were regressing.
We postulate, based on a study published following completion of our investigation 18 that reduced chondrosarcoma progression (e.g., cell proliferation component) of MeSG treated mice is from schweinfurthin's ability to modulate the oncogenic PI3K/ AKT/mTORC1 signaling pathway. A large number of cancers are linked to genetic or epigenetic dysregulation of the PI3K/AKT/mTORC1 signaling pathway that leads to uncontrolled cell proliferation. 42 A recent study identified schweinfurthin A's (Eisai Co., Japan) potent antiproliferative activity in select cancers (e.g., human glioblastoma, SF-539, and B-lymphoma, WSU-DLCL2), to be associated with its ability to block mTORC1 complex formation. 18 The lung cancer cell lines (including A549) were not affected by schweinfurthin A. Interestingly, in our hands LM1 and human glioblastoma, SF-295 cells are more sensitive to MeSG than normal rat cartilage and A549 cells, suggesting that dysregulation of the mTORC1 signaling pathway plays a prominent role in rat chondrosarcoma progression. In WSU-DLCL2 cancer cells, schweinfurthin was localized with oxysterol-binding proteins in vesicles associated with lipid raft-mediated PI3K activation. This was suggested to result in disruption of intracellular vesicular trafficking of the trans-Golgi network, leading to endoplasmic reticulum stress, and inhibition of mTORC1 complex formation. 18 Identification of the potent anti-proliferative properties of the natural product rapamycin (sirolimus) and its ability to inhibit mTOR complexes has led to development of a series of inhibitors of the PI3K/AKT/ mTORC1 pathway.
43 BEZ235 (a dual PI3K/mTORC1 inhibitor) treatment (for 72 h, our studies were for 48 h) of several human chondrosarcoma cell lines (SW1353, CS-1, JJ012, CH-2879, OUMS-27) resulted in growth inhibition for all cell lines with high sensitivity, having an IC 50 of less than 10 nM. 44 BEZ235 treated of nude mice with chondrosarcoma xenografts generated from a JJ012 cell line showed a significant decrease in tumor growth, and decrease cells expressing phosphorylated S6 protein (pS6, a downstream marker of PI3K/AKT/mTORC1 signaling pathway phosphorylated S6). Screening a range of low-to high-grade clinical conventional . The "reduced" safranin-O staining was not absolute and many of the intact cells of the treated group were very similar in intensity (arrow) to that of the Control, this suggests the putatively reduced staining is likely more related to the cell degeneration/necrosis rather directly to the treatment. Bars ¼ 385 and 155 mm, respectively. chondrosacroma samples showed 73 of 109 (69%) were positive for, pS6, suggesting this signaling pathway is a viable target for chondrosarcoma treatment. A recent study of rats containing the chondrosarcoma derived of the same tumor line used in our study SRC showed treatment with the mTOR inhibitor everolimus significantly reduced tumor progression. 45 Interestingly, in the rat tumor study neoplastic growth only was inhibited, 45 while in our mouse study treatment with MeSG showed reduced growth (reduced percent of Ki67 positive proliferating cells) and an increased apoptosis (increased in percent of caspase-3 positive apoptotic cells). Three out of ten treated tumor burden mice neoplasm were fully resolved. Further support of MeSG potent lethality of neoplastic tumor cells is shown by MeSG (50 nM) treatment of alginate cultured LM1 cells that showed no significance (p ¼ 0.370) increase in total number of cells over a 48 h period of treatment (e.g., implicating lack of cell proliferation), however a 39.5% reduction in viable cells (e.g., cellular lethality). Schweinfurthin's stimulation of neoplastic cell death suggests a role in addition to that associated with the oncogenic PI3K/AKT/mTORC1 signaling pathway, possibly involving stimulation of endoplasmic reticulum stress.
In brief we revealed the schweinfurthin, MeSG, as a tumor suppressor agent in a well-differentiated hyaline cartilage-like moderate-grade chondrosarcoma animal model. In hindsight, limitations of our animal studies included: (i) the absence of intermediate time of outcome measurements for capturing the time of impact and retention of MeSG potent anti-proliferative activity; (ii) absence of measurement of MeSG potency on the more aggressive parameters of the rat model (e.g., intraosseous administration and lung colonization); (iii) absence of outcome measurements of intermediate and downstream parameters of the PI3K/AKT/mTORC1 signaling and related pathways. We hope these results will prompt additional studies examining the feasibility of schweinfurthins in human chondrosarcoma cell lines, and as treatment for chondrosarcomas. The highly potent anti-cancer schweinfurthins have now become more readily available (Terpenoid Therapeutics, Inc., Coralville, IA and Eisai Co., Ltd, Japan) making further study more possible.
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